Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Sanofi Turns The Screws On Genzyme

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Sanofi-Aventis goes public with a $69-per-share offer for Genzyme, while the biotech rebuffs the offer as "opportunistic."

You may also be interested in...



Following Through On Prior Plan, Genzyme Sells Off Genetic Testing Unit

Sale of Genzyme Genetics for $925 million to LabCorp seen as enhancing the biotech's potential purchase value.

Following Through On Prior Plan, Genzyme Sells Off Genetic Testing Unit

Sale of Genzyme Genetics for $925 million to LabCorp seen as enhancing the biotech's potential purchase value.

Sanofi And Genzyme: Do Big Pharmas And Orphan Drugs Fit Together?

Big pharmas from Pfizer to GlaxoSmithKline are expanding their initiatives in niche disease areas, but if Sanofi-Aventis acquires Genzyme as it hopes, the French drug maker could soon emerge as an orphan drug leader

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

Australia To Seek Stakeholder Input On Terms Of HTA Review

A Milestone Moment For Pharmacogenomics: US FDA Ready To Drop ‘Voluntary’ Program

Electronic Records: US FDA Updates Guidelines On Use In Clinical Investigations

Device Component Of Intarcia’s Diabetes Treatment ITCA 650 Worries FDA

See All
UsernamePublicRestriction

Register

PS071115

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By